{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910780628203321"]
[null,null,"Titolo",null,"Endocrine therapies in breast cancer [[electronic resource] /] / edited by Aman U. Buzdar"]
[null,null,"Pubbl/distr/stampa",null,"Oxford ; ; New York, : Oxford University Press, 2007"]
[null,null,"ISBN",null,"0-19-173987-1"]
[{"$nulls":4},"0-19-960699-4"]
[{"$nulls":4},"1-283-58075-6"]
[{"$nulls":4},"9786613893208"]
[{"$nulls":4},"0-19-157517-8"]
[null,null,"Descrizione fisica",null,"1 online resource (129 p.)"]
[null,null,"Collana",null,"Oxford oncology library"]
[null,null,"Disciplina",null,"616.99/449071"]
[null,null,"Soggetti",null,"Breast - Cancer - Hormone therapy"]
[{"$nulls":4},"Breast - Cancer - Endocrine aspects"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Contents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; Z"]
[null,null,null,"Sommario/riassunto","Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging"]